CERYVYN THERAPEUTICS LIMITED ADR
WKN: A2QEW7 | ISIN: US68386J2087 | Ticker-Symbol: UKJ2Siehe auch CERYVYN THERAPEUTICS LIMITED
Frankfurt
17.03.25 | 08:52
3,000 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | CERYVYN THERAPEUTICS LIMITED: Change of Auditor | - | ASX | ||
| Fr | CERYVYN THERAPEUTICS LIMITED: Notice of Annual General Meeting/Proxy Form | 1 | ASX | ||
| 13.10. | CERYVYN THERAPEUTICS LIMITED: Change in substantial holding | 1 | ASX | ||
| 08.10. | CERYVYN THERAPEUTICS LIMITED: Change in substantial holding | - | ASX | ||
| 06.10. | CERYVYN THERAPEUTICS LIMITED: Change in substantial holding | - | ASX | ||
| 02.10. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | 2.415 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| 02.10. | CERYVYN THERAPEUTICS LIMITED: Change in substantial holding | - | ASX | ||
| CERYVYN THERAPEUTICS LIMITED ADR Aktie jetzt für 0€ handeln | |||||
| 24.09. | CERYVYN THERAPEUTICS LIMITED: Notification regarding unquoted securities - CYV | - | ASX | ||
| 22.09. | CERYVYN THERAPEUTICS LIMITED: Annual General Meeting Date | 2 | ASX | ||
| 14.09. | CERYVYN THERAPEUTICS LIMITED: Notification regarding unquoted securities - CYV | - | ASX | ||
| 08.09. | CERYVYN THERAPEUTICS LIMITED: Proposed issue of securities - CYV | - | ASX | ||
| 01.09. | CERYVYN THERAPEUTICS LIMITED: Proposed issue of securities - CYV | - | ASX | ||
| 31.08. | CERYVYN THERAPEUTICS LIMITED: Appendix 4G and Corporate Governance Statement | - | ASX | ||
| 31.08. | CERYVYN THERAPEUTICS LIMITED: Appendix 4E and 2026 Annual Report | - | ASX | ||
| 21.08. | CERYVYN THERAPEUTICS LIMITED: Notification regarding unquoted securities - CYV | 1 | ASX | ||
| 27.07. | CERYVYN THERAPEUTICS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 17.07. | CERYVYN THERAPEUTICS LIMITED: Update to Executive Chair Remuneration Arrangements | - | ASX | ||
| 13.07. | CERYVYN THERAPEUTICS LIMITED: Notification of cessation of securities - CYV | - | ASX | ||
| 10.07. | CERYVYN THERAPEUTICS LIMITED: Change of Company's Constitution | - | ASX | ||
| 08.07. | OPTHEA LIMITED: Change of Company Name, ASX Code and Registered Office | 1 | ASX |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 5,550 | 0,00 % | Palatin Technologies, Inc.: Palatin Reports Fiscal Year 2026 Financial Results and Provides Business Update | Programs are focused on rare obesity disorders associated with the melanocortin 4 receptor (MC4R) pathway, including hypothalamic obesity, Prader-Willi syndrome... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 5,360 | 0,00 % | Cosciens Biopharma Inc (2): Cosciens raises $12M of up to $20M debenture deal | ||
| HALOZYME THERAPEUTICS | 110,85 | -0,27 % | H.C. Wainwright reiterates Halozyme stock rating on Takeda trial data | ||
| ABCELLERA BIOLOGICS | 10,680 | -2,02 % | AbCellera-Aktie mit +450% - nächstes Ziel 20 US$? | Die AbCellera-Aktie hat innerhalb weniger Monate eine beeindruckende Rallye hingelegt. Vom Frühjahrstief bei rund 3,00 US$ stieg der Kurs zeitweise bis auf 15,00 US$. Nach diesem Anstieg läuft nun eine... ► Artikel lesen | |
| GLOW LIFETECH | 0,013 | -13,33 % | Smallcap Discoveries: Glow Lifetech Corp. to Present at the Annual Smallcap Discoveries Conference in Vancouver | Toronto, Ontario--(Newsfile Corp. - September 24, 2026) - Glow Lifetech Corp. (CSE: GLOW) (OTCID: GLWLF) (FSE: 9DO) ("Glow" or the "Company") is pleased to announce that it will be participating in... ► Artikel lesen | |
| BIO-RAD LABORATORIES | 317,00 | -1,37 % | ROUNDUP/'WSJ': US-Investor Elliot steigt bei Sartorius-Großaktionär Bio-Rad ein | NEW YORK (dpa-AFX) - Der US-Investor Elliott hat laut einem Medienbericht eine beachtliche Beteiligung an dem Sartorius-Großaktionär Bio-Rad Laboratories aufgebaut. Der aktivistische Investor wolle... ► Artikel lesen | |
| AVID BIOSERVICES | - | - | Avid Bioservices Appoints Maria Ebro Andreasen as Chief People Officer to Fuel Continued Growth and Talent Strategy | Company expands team, university partnerships, and internship programs to build long-term biologics talent pipeline.TUSTIN, Calif., May 18, 2026 /PRNewswire/ -- Avid Bioservices, a leading... ► Artikel lesen | |
| BIOLINERX | 1,630 | -5,78 % | BioLineRx Ltd.: BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update | - Second of five planned cohorts ongoing in Phase 1/2a trial of GLIX1 in GBM; third patient cohort expected to commence dosing in September -
- Announced new data... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 2,016 | -4,55 % | Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in Two Upcoming Investor Conferences | BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| WHITEHAWK THERAPEUTICS | 2,840 | +7,58 % | Whitehawk Therapeutics, Inc.: Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights | Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026
Cash, cash equivalents and short-term... ► Artikel lesen | |
| INNOVENT BIOLOGICS | 9,096 | -9,09 % | CMBI Raises INNOVENT BIO TP to HKD138.63, IBI3003 Clinical Data Validate Leadership in MM TCE Field | ||
| OVID THERAPEUTICS | 2,160 | +3,85 % | Ovid Therapeutics Inc.: Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results | First-ever oral direct KCC2 activator, OV4071, advancing in an ongoing Phase 1 studyInitiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitorA... ► Artikel lesen | |
| GEOVAX LABS | 0,232 | 0,00 % | EQS-News: GeoVax, Inc.: GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026 | EQS-News: GeoVax, Inc.
/ Key word(s): Science
GeoVax to Highlight Next-Generation MVA Vaccine and Manufacturing Advances at World Vaccine Congress Europe 2026 06.10.2026 / 14:37... ► Artikel lesen | |
| COCRYSTAL | 0,805 | 0,00 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen |
Das Unternehmen CERYVYN THERAPEUTICS LIMITED ADR kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 3,000 Euro und damit 0,00 % im Plus. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERYVYN THERAPEUTICS LIMITED ADR finden Sie auf Wallstreet Online.